No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
OPRX OptimizeRx
- 9.320
- -0.030-0.32%
Close Apr 19 16:00 ET
- 9.320
- 0.0000.00%
Post 16:02 ET
169.47MMarket Cap-9048P/E (TTM)
9.560High9.170Low298.86KVolume9.250Open9.350Pre Close2.79MTurnover1.98%Turnover RatioLossP/E (Static)18.18MShares16.64552wk High1.34P/B140.65MFloat Cap6.92052wk Low--Dividend TTM15.09MShs Float99.178Historical High--Div YieldTTM4.17%Amplitude6.502Historical Low9.327Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), Alvotech (ALVO) and Pacific Biosciences (PACB)
Navigating New Horizons: Optimizerx Corporation's Strategic Pivot Raises Financial Risk Flags
Express News | JMP Securities Reiterates Market Outperform on OptimizeRx, Maintains $15 Price Target
Analysts Are Bullish on These Healthcare Stocks: OptimizeRx (OPRX), Day One Biopharmaceuticals (DAWN)
Earnings Flash (OPRX) OPTIMIZERX CORPORATION Posts Q4 Revenue $28.4M
07:10 AM EDT, 04/16/2024 (MT Newswires) -- Earnings Flash (OPRX) OPTIMIZERX CORPORATION Posts Q4 Revenue $28.4M
Express News | OptimizeRx Sees FY24 Revenue Of $100M Vs. $104.73M Est
Comments
Recent insider selling at OptimizeRx, especially by Marion Odence-Ford, may worry potential investors. The absence of insider buying and insignificant share ownership by insiders hint at possible doubts about future performance.
OptimizeRx's Stock Sinks To US$12.92, But Insiders Sold Even Lower 2
OptimizeRx's high P/S ratio may suggest that investors anticipate a turnaround in the company's revenue performance. This could indicate shareholders' strong future revenue expectations.
The high P/S ratio at OptimizeRx suggests investors expect a reversal of the company's downtrend in revenue. Shareholders seem to hold stocks with hope for the company's promising future.
Investors at OptimizeRx might be anticipating a reversal in its poor revenue performance, hence the high P/S ratio. Shareholders potentially retain stocks expecting the company's bright future.
Investors at OptimizeRx may be expecting a turnaround in the company's poor revenue performance, hence the high P/S ratio. This could reflect shareholders' strong future revenue expectations.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg